BRPI0921313A2 - composição farmaucêutica - Google Patents

composição farmaucêutica

Info

Publication number
BRPI0921313A2
BRPI0921313A2 BRPI0921313A BRPI0921313A BRPI0921313A2 BR PI0921313 A2 BRPI0921313 A2 BR PI0921313A2 BR PI0921313 A BRPI0921313 A BR PI0921313A BR PI0921313 A BRPI0921313 A BR PI0921313A BR PI0921313 A2 BRPI0921313 A2 BR PI0921313A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BRPI0921313A
Other languages
English (en)
Inventor
Domenico Fanara
Frédéric Eeckman
Monique Berwaer
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of BRPI0921313A2 publication Critical patent/BRPI0921313A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
BRPI0921313A 2008-11-18 2009-11-17 composição farmaucêutica BRPI0921313A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08105817 2008-11-18
EP09100312 2009-06-02
PCT/EP2009/065271 WO2010057870A1 (en) 2008-11-18 2009-11-17 Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative

Publications (1)

Publication Number Publication Date
BRPI0921313A2 true BRPI0921313A2 (pt) 2015-12-29

Family

ID=41381618

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921313A BRPI0921313A2 (pt) 2008-11-18 2009-11-17 composição farmaucêutica

Country Status (18)

Country Link
US (3) US10172805B2 (pt)
EP (1) EP2358360B1 (pt)
JP (2) JP5954890B2 (pt)
KR (1) KR101689688B1 (pt)
CN (2) CN104208714A (pt)
AU (1) AU2009317280B2 (pt)
BR (1) BRPI0921313A2 (pt)
CA (1) CA2741041C (pt)
DK (1) DK2358360T3 (pt)
EA (1) EA019572B1 (pt)
ES (1) ES2602604T3 (pt)
HK (1) HK1159503A1 (pt)
HU (1) HUE032275T2 (pt)
IL (1) IL212447A (pt)
MX (1) MX339852B (pt)
PL (1) PL2358360T3 (pt)
PT (1) PT2358360T (pt)
WO (1) WO2010057870A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107243007A (zh) 2008-10-16 2017-10-13 约翰斯.霍普金斯大学 改善认知功能的方法和组合物
HUE032275T2 (en) * 2008-11-18 2017-09-28 Ucb Biopharma Sprl Sustained release formulations containing a 2-oxo-pyrrolidine derivative
WO2011107855A2 (en) * 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Sustained release oral liquid suspension dosage form
EP2563339A1 (en) * 2010-04-29 2013-03-06 Lupin Limited Controlled release pharmaceutical compositions of brivaracetam
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
CN112843005B (zh) 2015-05-22 2023-02-21 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
EP3127539A1 (en) * 2015-08-03 2017-02-08 Latvian Institute Of Organic Synthesis Use of 2-(5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures
WO2017117569A1 (en) 2015-12-30 2017-07-06 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
CN111407738A (zh) * 2020-04-03 2020-07-14 江苏艾立康药业股份有限公司 一种布立西坦控释制剂及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6327424A (ja) 1986-07-17 1988-02-05 Shionogi & Co Ltd 徐放性製剤およびその製造法
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5622716A (en) 1987-02-20 1997-04-22 Farmarc Nederland B.V. Process for preparing a retard product containing diltiazem for a single daily administration
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
EP0452862B1 (en) * 1990-04-18 1995-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Spherical seed cores, spherical granules and process for production thereof
JP2558396B2 (ja) * 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
JPH10182438A (ja) * 1991-03-07 1998-07-07 Takeda Chem Ind Ltd 有核散剤
DE19630035A1 (de) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
CA2507685A1 (en) 2002-11-28 2004-06-10 Themis Laboratories Private Limited Process for manufacturing sustained release microbeads containing venlafaxine hci
DE10353186A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
WO2006088864A1 (en) * 2005-02-16 2006-08-24 Elan Pharma International Limited Controlled release compositions comprising levetiracetam
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
BRPI0609598A2 (pt) * 2005-03-29 2010-04-20 Roehm Gmbh forma farmacêutica multiparticulada compreendendo péletes com uma substáncia possuindo um efeito modular em relação à liberação de ingrediente ativo
WO2006125074A1 (en) * 2005-05-17 2006-11-23 Brown University Research Foundation Drug delivery formulations for targeted delivery
US20070264346A1 (en) * 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
FR2897267A1 (fr) 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
US8211936B2 (en) 2006-06-08 2012-07-03 Ucb Pharma, S.A. Co-crystals of pyrrolidinones
DE102006035549A1 (de) * 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
JP5513113B2 (ja) * 2006-08-31 2014-06-04 アプタリス ファーマテック,インコーポレイテッド 弱塩基性薬剤の固溶体を含む薬剤送達システム
CN101801356B (zh) 2007-09-21 2016-10-19 赢创罗姆有限公司 耐受乙醇影响的非阿片类的pH依赖性受控释放的药物组合物
WO2009102964A2 (en) * 2008-02-14 2009-08-20 Nordson Corporation Apparatus for testing containers, tray for holding cylinders and suction-basedchuck for robotic arm
HUE032275T2 (en) * 2008-11-18 2017-09-28 Ucb Biopharma Sprl Sustained release formulations containing a 2-oxo-pyrrolidine derivative
PL2358361T3 (pl) * 2008-11-18 2017-02-28 Ucb Biopharma Sprl Preparaty o przedłużonym uwalnianiu zawierające pochodną 2-okso-1-pirolidyny

Also Published As

Publication number Publication date
JP2012509357A (ja) 2012-04-19
JP2015120756A (ja) 2015-07-02
KR20110089182A (ko) 2011-08-04
ES2602604T3 (es) 2017-02-21
EA201100752A1 (ru) 2012-01-30
AU2009317280A1 (en) 2010-05-27
US20200085754A1 (en) 2020-03-19
MX339852B (es) 2016-06-15
US10172805B2 (en) 2019-01-08
HK1159503A1 (en) 2012-08-03
CA2741041C (en) 2015-01-13
CN102215829B (zh) 2014-12-10
HUE032275T2 (en) 2017-09-28
MX2011004816A (es) 2011-05-30
KR101689688B1 (ko) 2016-12-26
PL2358360T3 (pl) 2017-02-28
CN102215829A (zh) 2011-10-12
US20190142759A1 (en) 2019-05-16
IL212447A0 (en) 2011-06-30
EA019572B1 (ru) 2014-04-30
AU2009317280B2 (en) 2014-03-06
US20110250282A1 (en) 2011-10-13
IL212447A (en) 2016-10-31
CN104208714A (zh) 2014-12-17
EP2358360A1 (en) 2011-08-24
DK2358360T3 (en) 2016-12-12
JP5954890B2 (ja) 2016-07-20
CA2741041A1 (en) 2010-05-27
PT2358360T (pt) 2016-11-15
WO2010057870A1 (en) 2010-05-27
EP2358360B1 (en) 2016-09-14

Similar Documents

Publication Publication Date Title
LTPA2018014I1 (lt) Farmacinė kompozicija 514
LTC2140867I2 (lt) Farmacinė kompozicija
SMT201600259B (it) Composizioni farmaceutiche antibatteriche
SMT201700095B (is) Composizioni farmaceutiche per inalazione
BRPI0721651A2 (pt) Composição farmacêutica
DK3097925T3 (da) Farmaceutisk sammensætning
BRPI0920521A2 (pt) combinação farmacêutica
BRPI1004940A2 (pt) composição farmacêutica
DE602008002756D1 (de) Bauzusammensetzung
BRPI0906749A2 (pt) Composição
BRPI0913808A2 (pt) composição
RU2493831C3 (ru) Фармацевтические композиции
BRPI1015939A2 (pt) composição farmacêutica
DK2120884T3 (da) Farmaceutisk sammensætning
IT1392101B1 (it) Composizione comprendente isoflavoni
BRPI0917231A2 (pt) composição
DK2285413T3 (da) Farmaceutisk sammensætning
BRPI1012539A2 (pt) composições farmacêuticas
BRPI0921313A2 (pt) composição farmaucêutica
IT1394400B1 (it) Composizioni farmaceutiche
BRPI0921654A2 (pt) formulação farmacêutica
DK2285357T3 (da) Farmaceutisk sammensætning omfattende brivaracetam
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
DK2271618T3 (da) Farmaceutiske forbindelser
BRPI0820198A2 (pt) composições farmacêuticas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.